BrianJayDrukerMD

Oncology • Portland, OR

Hematologic Oncology

Professor of Medicine, Oregon Health & Sci University

Join to view full profile

Dr. Druker is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Druker's full profile

Already have an account?

Office
3181 Sw Sam Jackson Park Rd, L952
Portland, OR 97239
Phone+1 503-494-5596

Fax+1 503-494-3688

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1984 - 1987
Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 1981 - 1984
University of California San Diego School of MedicineClass of 1981

Certifications & Licensure

OR State Medical License 1993 - 2025
WA State Medical License 2022 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2007-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
Portland Monthly Magazine Castle Connolly, 2011
Elected Member Institute of Medicine, 2003
Elected Member The American Society for Clinical Investigation, 1997
Whos Who in Medicine and Healthcare Marquis Whos Who
Investigator Howard Hughes Medical Institute
Join now to see all

Clinical Trials

A Phase I Study of Oral Asciminib (ABL001) in Patients With CML or Ph+ ALL Start of enrollment: 2014 Apr 24
Completed
Phase 1

Publications & Presentations

PubMed

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.
Christopher A Eide, Diana Brewer, Tao Xie, Anna Reister Schultz, Samantha L Savage
Cancer Cell. 2024-09-09
1 citations
CML and the WHO: Why?
Ellin Berman, Neil P Shah, Michael Deninger, Jessica K Altman, Maria Amaya
Journal of Clinical Oncology. 2024-03-20
7 citations
A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.
Sheng F Cai, Ying Huang, Jennie R Lance, Hsiaoyin Charlene Mao, Andrew J Dunbar
Blood Advances. 2024-01-23

Journal Articles

CRISPR-Cas9–Mediated Saturated Mutagenesis Screen Predicts Clinical Drug Resistance with Improved Accuracy
Richard D Press, Brian J Druker, Michael R Green, Proceedings of the National Academy of Sciences

Press Mentions

AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer ResignsDecember 5th, 2024
Dr. Brian Druker Announces His Resignation as OHSU Knight Cancer Institute CEODecember 3rd, 2024
OHSU Experts Elected to the National Academy of Medicine, One of the Highest Honors in the Fields of Health, MedicineOctober 21st, 2024
Join now to see all

Grant Support

Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute2011–2012
Senior LeadershipNational Cancer Institute2011
Protocol Specific Research SupportNational Cancer Institute2011
Protocol Review &Monitoring SystemNational Cancer Institute2011
Proteomics Shared ResourceNational Cancer Institute2011
Program Planning And EvaluationNational Cancer Institute2011
Program LeadershipNational Cancer Institute2011
Histapathology &Cancer Genotyping Shared ResourceNational Cancer Institute2011
Flow Cytometry Shared ResourceNational Cancer Institute2011
Developmental FundsNational Cancer Institute2011
Data Safety Monitoring SystemsNational Cancer Institute2011
Clinical Research Management Shared ResourceNational Cancer Institute2011
Bioanalytical/Pharacokinetic Shared ResourceNational Cancer Institute2011
AdministrationNational Cancer Institute2011
Ohsu Knight Cancer InstituteNational Cancer Institute2009–2011
Ohsu Knight Cancer Institute- Community Health Educator SupplementNational Cancer Institute2010
Ohsu Knight Cancer Institute - Rapid SupplementNational Cancer Institute2010
Accelerating Target Identification And Validation In Leukemia: Integrating Sirna-National Cancer Institute2009–2010
Chronic Myelogenous Leukemia And BCR-ABL SubstratesNational Cancer Institute1995–2009
Ohsu Cancer InstituteNational Cancer Institute2007–2008
Cancer And KinasesNational Cancer Institute2005
CBL Function In Cellular Signaling And TransformationNational Cancer Institute1999–2003
Tyrosine Kinase Inhibitors As Antineoplastic AgentsNational Cancer Institute1999–2001
Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1993–1994
Genetic Analysis Of The Activation Of A Tyrosine KinaseNational Cancer Institute1990–1992
Mutagenesis Of Polyoma Middle-T AntigenNational Cancer Institute1986